Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Peptide-based COVID-19 vaccine - 21/04/2022 A 96-well analysis plate with depressions of varying darkness is shown, held up by two gloved hands.

    CoVac-1: T-cell activator against COVID-19

    Current vaccines against COVID-19 aim at forming neutralising antibodies that prevent the virus from penetrating the host cells. Since people with impaired B-cell immune responses – which can also occur in cancer or autoimmune diseases – are not able to do this, researchers at the University of Tübingen have developed the peptide-based T-cell activator CoVac-1, which promises broad and long-term immunity.

    https://www.gesundheitsindustrie-bw.de/en/article/news/covac-1-t-cell-activator-against-covid-19
  • Press release - 12/04/2022

    Technology transfer award for PCR rapid test device for infection diagnostics

    Spindiag GmbH, together with the University of Freiburg and the Hahn-Schickard-Gesellschaft für angewandte Forschung e.V., was awarded the Technology Transfer Prize 2020 from the German Physical Society (DPG) on April 09, 2022 for the development of the PCR-based rapid test system Rhonda.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/technology-transfer-award-pcr-rapid-test-device-infection-diagnostics
  • Macrophages interacting with cytomegaloviruses - 22/02/2022 Graphik_CMV_Makrophagen_Teaser.jpg

    Cytomegaloviruses subvert macrophage identity

    Cytomegaloviruses are basically harmless. However, if they occur along with other pathogens, they can trigger serious diseases. They can manipulate our immune system and encourage resident defence cells to migrate. Researchers at the Centre for Chronic Immunodeficiency (CCI) at the Freiburg University Medical Centre have discovered which mechanisms underlie the behavioural changes in macrophages that make it easier for other pathogens to attack.

    https://www.gesundheitsindustrie-bw.de/en/article/news/cytomegaloviruses-subvert-macrophage-identity
  • Biosensor for whole blood and exhaled breath analysis - 02/02/2022 Nahaufnahme eines Multiplex-Chips mit roten oder blauen Kanälen, der zwischen zwei Fingern in blauen Handschuhen gehalten wird.

    Antibiotic detection from whole blood or exhaled breath possible

    Incorrectly dosed antibiotics are not only dangerous for patients, but also often the cause of resistant strains of bacteria. Researchers at the University of Freiburg have developed a biosensor to determine the effective amount and thus enable personalised therapy. The biosensor works by rapidly determining small amounts of the substances directly from whole blood or exhaled breath.

    https://www.gesundheitsindustrie-bw.de/en/article/news/antibiotic-detection-whole-blood-or-exhaled-breath-possible
  • Viral zoonoses - 24/01/2022 Schematic drawing of a flavivirus polyprotein anchored in the ER membrane. The different viral proteins are indicated by differently coloured sections on the polyprotein that is marked with dashes and the protease interfaces are marked by arrows.

    Development of inhibitors that help stop viral zoonoses

    Emerging viral infections such as COVID-19 or Zika disease pose an increasing threat to humans. At the Institute of Pharmacy and Molecular Biotechnology (IPMB) at Heidelberg University, Prof. Dr. Christian Klein's research group is developing inhibitors against already known viruses in the hope that these can also be used against new virus variants.

    https://www.gesundheitsindustrie-bw.de/en/article/news/development-inhibitors-help-stop-viral-zoonoses
  • Press release - 19/11/2021

    Keep an eye on us! – Bacteria on slit lamps

    Furtwangen University publishes the world’s first molecular biological study on bacterial contamination of slit lamps. Slit lamps are among the most important tools used by ophthalmologists and opticians. They allow selected areas of the eye to be magnified and examined for diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/keep-eye-us-bacteria-slit-lamps
  • Booster for neutrophil granulocytes - 27/10/2021 acetat-aktivierung_Bearbeitet.jpg

    Acetate supports immune cells to fight against sepsis

    Blood poisoning is the most dangerous complication of bacterial infections and often leads to death. Researchers at the Interfaculty Institute of Microbiology and Infection Medicine at the University of Tübingen have now identified acetate as a potent agent for stimulating innate immune system cells, supporting their ability to destroy bacteria.

    https://www.gesundheitsindustrie-bw.de/en/article/news/acetate-supports-immune-cells-fight-against-sepsis
  • Press release - 13/10/2021

    Tackling the collateral damage from antibiotics

    EMBL scientists pave the way for reducing the harmful side effects antibiotics have on gut bacteria. Antibiotics help us to treat bacterial infections and save millions of lives each year. But they can also harm the helpful microbes residing in our gut, weakening one of our body’s first lines of defence against pathogens and compromising the multiple beneficial effects our microbiota has for our health.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tackling-collateral-damage-antibiotics
  • Press release - 20/08/2021

    Innovative Drug Discovery

    New drugs are intended to help stop viral zoonoses – infections that jump from animals to humans. To study suitable inhibitors, Prof. Dr Christian Klein from the Institute of Pharmacy and Molecular Biotechnology (IPMB) of Heidelberg University is receiving funding in the amount of 450,000 euros from the Volkswagen Foundation.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovative-drug-discovery
  • Press release - 13/07/2021

    Breakthrough in research on age-related macular degenerationtion

    Age-related macular degeneration (AMD) is the commonest cause of blindness in developed countries affecting seven million in total in Germany, from which 500,000 people are suffering from late stage disease, around half of whom are registered as visually impaired. There are two forms of AMD, ‘wet’ and ‘dry’. There are currently no treatments available for the dry form of the disease (geographic atrophy).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/breakthrough-research-age-related-macular-degenerationtion
  • Press release - 25/05/2021

    From harmless skin bacteria to dreaded pathogens

    The bacterium Staphylococcus epidermidisis primarily a harmless microbe found on the skin and in the noses of humans. Yet some strains of this species can cause infections – in catheters, artificial joints, heart valves, and in the bloodstream – which are difficult to treat. These bacteria are often resistant to a particularly effective antibiotic, methicillin, and are among the most feared germs in hospitals.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/harmless-skin-bacteria-dreaded-pathogens
  • Vaccine development - 25/05/2021 AdobeStock_385688184_CROCOTHERY.jpg

    Vaccines - a beacon of hope in the fight against pandemics

    Having long been considered less lucrative for the big pharmaceutical companies, vaccine development is taking off in an unforeseen way in the wake of the COVID-19 pandemic. Financial support is flooding in and all kinds of vaccine development strategies are being deployed. Among the winners in the competition for effective coronavirus vaccines are vaccines based on RNA technology.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/vaccines-beacon-hope-fight-against-pandemics
  • Signal mechanisms in inflammatory processes - 18/05/2021 aktivierte-makrophagen.jpg

    Newly discovered substances activate the inflammasome in macrophages

    Low-grade chronic inflammation caused by components of the innate immune system may increase the risk of developing a variety of diseases in the long term. In their search for the signalling mechanisms underlying these inflammatory processes, Prof. Dr. Olaf Groß' research group at the Freiburg University Medical Centre discovered new active substances with immunostimulatory properties that may open up additional possibilities in cancer…

    https://www.gesundheitsindustrie-bw.de/en/article/news/newly-discovered-substances-activate-inflammasome-macrophages
  • Article - 29/04/2021 aufbau-antikoerper.jpg

    Nanobodies for determining neutralising antibodies after corona infection

    After contact with a pathogen, ideally our immune system generates neutralising antibodies to prevent a future infection. With NeutrobodyPlex, scientists from Reutlingen and Tübingen have developed a highly specific test procedure based on single-domain antibodies (nanobodies) that can be used to easily and reliably determine the quality of the immune response against the novel coronavirus.

    https://www.gesundheitsindustrie-bw.de/en/article/news/nanobodies-determining-neutralising-antibodies-after-corona-infection
  • Article - 17/03/2021 Schematische Abbildung des Tetracyclin-induzierbaren epigenetischen Gedächtnissystems in einem Escherichia coli Bakterium.

    Epigenetic switches in bacteria as biosensors

    The analysis of pathogen biomarkers and biomarkers for the diagnosis of diseases can be crucial for health. However, the detection of pathogens and diseases depends on a sensitive and reliable method that delivers rapid results. Biosensors have such properties. Researchers at the Institute of Biochemistry and Technical Biochemistry (IBTB) at Stuttgart University have constructed an epigenetic circuit composed of plasmids that might make it…

    https://www.gesundheitsindustrie-bw.de/en/article/news/epigenetic-switches-bacteria-biosensors
  • Press release - 15/03/2021

    How novel pathogens may cause the development of colorectal cancer

    Do BMMFs, the novel infectious agents found in dairy products and bovine sera, play a role in the development of colorectal cancer? Scientists led by Harald zur Hausen detected the pathogens in colorectal cancer patients in close proximity to tumors. The researchers show that the BMMFs trigger local chronic inflammation, which can cause mutations via activated oxygen molecules and thus promote cancer development in the long term.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-novel-pathogens-may-cause-development-colorectal-cancer
  • Press release - 24/02/2021

    Supposedly "silent" mutation with serious consequences

    So-called silent mutations have no effect on the composition of a protein. They are therefore not considered to promote cancer. However, scientists from the German Consortium for Translational Cancer Research (DKTK), partner site Essen, now describe in a case of kidney cancer an overlooked silent mutation with a major impact on prognosis.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/supposedly-silent-mutation-serious-consequences
  • Article - 17/02/2021 Messerer_Bild_2.jpg

    Whole blood model enables development of early warning system for sepsis

    Sepsis is a life-threatening disease that can be treated all the more successfully the faster therapy is initiated. It is not just the infection itself that is so dangerous, but a dysregulated response of the immune system. Physicians at Ulm University Hospital have now developed an animal-free test system that can be used to research the disease and develop innovative diagnostic tools to quickly assess a patient's sepsis risk and optimise…

    https://www.gesundheitsindustrie-bw.de/en/article/news/whole-blood-model-enables-development-early-warning-system-sepsis
  • Press release - 01/02/2021

    Targeting a rapid market breakthrough for new vaccine production method

    In a so-called inactivated or killed vaccine, the virus particles it contains are first rendered inactive by means of the toxic chemical formaldehyde. A better way of achieving this, however, is to irradiate the pathogens with low-energy electrons. Four Fraunhofer Institutes have now developed a new method of vaccine production based on this technique that is not only quicker but also guarantees a higher quality of product.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/targeting-rapid-market-breakthrough-new-vaccine-production-method
  • Press release - 18/01/2021

    How a protein variant could explain resistance to sleeping sickness drug

    A specific variant of the surface protein VSG of African trypanosomes, the causative agents of sleeping sickness, is associated with resistance to the important drug Suramin. Scientists at the German Cancer Research Center have now been able to find a possible explanation for the formation of resistance based on the crystal structure of this protein variant.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-protein-variant-could-explain-resistance-sleeping-sickness-drug
  • Infection control - 07/01/2021 Elektronenmikroskopische Aufnahme von pink gefärbten Staphylococcus aureus Bakterien auf einer lila gefärbten Zelloberfläche.

    Gene accordions as potential markers for pathogenic properties

    Bacteria must react to changes in the environment in order to survive. This is partly done by adapting genetic material, for example by multiplying and shortening individual genome segments. The research group led by Dr. Simon Heilbronner from the Interfaculty Institute of Microbiology and Infection Medicine at the University of Tübingen has shown that these so-called gene accordions are frequently found in the bacterium Staphylococcus aureus.

    https://www.gesundheitsindustrie-bw.de/en/article/news/gene-accordions-potential-markers-pathogenic-properties
  • Intestinal peptide heals lung - 14/10/2020 Die Immuntherapie (ICI)  aktiviert Effektor-T-Zellen  und reduziert auf der anderen Seite regulatorische T-zellen, um den Tumor zu besiegen (schwarze Zellen). Die durch die Immuntherapie ausgelöste Lungenentzündung wird mit Steroidtherapie (Cortison) oder mit inhaliertem VIP (vasoaktives intestinales Peptid) behandelt. Unter VIP kommt es zur Dämpfung der Entzündung.

    Inhalation of intestinal hormone VIP helps against immunotherapy-induced pneumonia

    If cancer patients develop pneumonitis, an inflammation of the lungs resulting from immunotherapy, their symptoms and restrictions in lung function can often only be alleviated with cortisone. Researchers led by Prof. Dr. Joachim Müller-Quernheim and Dr. Björn Frye from the Freiburg University Medical Centre have been able to cure a patient's pneumonitis by inhalation of a long-known neuropeptide.

    https://www.gesundheitsindustrie-bw.de/en/article/news/inhalation-intestinal-hormone-vip-helps-against-immunotherapy-induced-pneumonia
  • KyooBe Tech GmbH - 08/10/2020 Scheme of the patented pump and roll system (LEEI technology).

    Next generation vaccine production

    For decades, conventional inactivated vaccines have been produced by killing pathogens with toxic chemicals. However, this process often changes the surface structure of the pathogens to such an extent that the immune system is only able to induce a weak response. KyooBe Tech GmbH is offering a method that uses low-energy electrons to inactivate pathogens. Vaccines produced this way are much higher quality, making them safer and more effective.

    https://www.gesundheitsindustrie-bw.de/en/article/news/next-generation-vaccine-production
  • Mosses for pharmaceutical production - 16/09/2020 Eleva_Bild_1.jpg

    Factor H as a therapeutic option for viral diseases - including COVID-19

    The search for drug candidates for COVID-19 diseases is well underway. Factor H, which is part of the innate immune system, might also be a future therapeutic option. The Freiburg-based biotech company eleva has developed a technology for producing this human protein in moss cells. The active ingredient, which might also have a regulatory effect in other diseases, is currently undergoing preclinical testing.

    https://www.gesundheitsindustrie-bw.de/en/article/news/factor-h-therapeutic-option-viral-diseases-including-covid-19
  • CeGat GmbH - 06/08/2020 Cegat_Teaser.jpg

    CeGaT: Specific coronavirus antibody test for all

    Have I perhaps already had COVID-19 in the past? This is a question many of us have been asking. Reliable tests that would provide the answer have simply not been available until now. However, the Tübingen-based biotech company CeGaT is now offering a coronavirus antibody test to anyone who wants one, thus answering this question with the highest probability currently possible. Response to the offer has been huge in the few weeks since the test…

    https://www.gesundheitsindustrie-bw.de/en/article/news/cegat-specific-coronavirus-antibody-test-all

Page 3 / 4

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2025
Website address: https://www.gesundheitsindustrie-bw.de/en/search